Beyond contingency awareness: the role of influence awareness in resisting conditioned attitudes.

Evaluative conditioning procedures change people's evaluations of stimuli that are paired with pleasant or unpleasant items. To test whether influence awareness allows people to resist such persuasive attempts, we conducted three experiments. In the first two experiments featuring low levels of influence awareness (N1 = 96, N2 = 93) we manipulated the degree of control people have in expressing their attitudes, by providing participants in one condition with the option to "pass" rather than respond, when they felt influenced in their evaluations of conditioned stimuli. In the third experiment (N3 = 240) we manipulated the level of influence awareness by using a warning instruction similar to the one found in prior controllability studies, while giving everyone the option to pass the evaluation when they felt influenced. All studies found that participants often failed to use the skip option to exert control over conditioned preferences. In some cases, this may be because participants failed to notice the pairings, but in most cases because participants lacked awareness that the pairings could influence them. Even when explicitly warned that the pairings could influence them, participants seemed to believe that they were not vulnerable to such effects.

A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.

Novel agents have provided a new foundation for multiple myeloma therapies. When combined with other anti-myeloma agents, these compounds significantly enhance clinical efficacy. High-dose steroids are frequently used in anti-myeloma combination regimens; however, the doses employed are often poorly tolerated, especially in patients with concurrent comorbid conditions. We hypothesized that a steroid-independent combination regimen could be developed without significant compromise of efficacy. The availability of such a regimen will be important for patients whose concurrent ailments make them poor candidates for steroid containing anti-myeloma regimens. A phase II single institute, non-randomized clinical trial was conducted to investigate a novel steroid-free three-drug combination of bortezomib (V), pegylated liposomal doxorubicin (D), and thalidomide (T), the VDT regimen. Forty-three newly diagnosed multiple myeloma patients requiring treatment were enrolled on this study. The overall response rate and complete response (CR) + near complete response (nCR) rate was 78% and 35%, respectively. Median time to progression was 29·5 months. Fatigue, rash, neuropathy, constipation and infections were the most common side effects. We concluded that VDT is a tolerable and an effective regimen capable of inducing high response rates and can be employed in patients considered to be poor candidates for steroid-based treatment regimens.